{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:26:18Z","timestamp":1772112378136,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.brachy.2025.11.001","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:59:43Z","timestamp":1767761983000},"page":"325-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ultrasound and CT-guided 125I implantation combined with TACE therapy in the treatment of recurrent HCC after RFA"],"prefix":"10.1016","volume":"25","author":[{"given":"Ningjie","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulei","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xizi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.brachy.2025.11.001_bib0001","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.brachy.2025.11.001_bib0002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"45","key":"10.1016\/j.brachy.2025.11.001_bib0003","first-page":"17245","article-title":"Comparison of recurrence patterns between radiofrequency ablation and surgical resection for hepatocellular carcinoma","volume":"20","author":"Imai","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.brachy.2025.11.001_bib0004","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14737140.2023.2203387","article-title":"Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation","volume":"23","author":"Bosi","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"10.1016\/j.brachy.2025.11.001_bib0005","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamaoncol.2024.1831","article-title":"Survival in patients with recurrent intermediate-stage hepatocellular carcinoma: sorafenib plus TACE vs TACE alone randomized clinical trial","volume":"10","author":"Fan","year":"2024","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.brachy.2025.11.001_bib0006","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1002\/cam4.5880","article-title":"Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: a multicenter, retrospective study","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.brachy.2025.11.001_bib0007","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.brachy.2025.11.001_bib0008","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00432-013-1568-0","article-title":"Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial","volume":"140","author":"Yang","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.brachy.2025.11.001_bib0009","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/13645706.2022.2033786","article-title":"I-125 seeds insertion with TACE for advanced HCC: a meta-analysis of randomized controlled trials","volume":"31","author":"Hou","year":"2022","journal-title":"Minim Invasive Ther Allied Technol"},{"issue":"4","key":"10.1016\/j.brachy.2025.11.001_bib0010","first-page":"775","article-title":"125I seed implantation combined with TACE for advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"16","author":"Wang","year":"2020","journal-title":"J Cancer Res Ther"},{"issue":"0","key":"10.1016\/j.brachy.2025.11.001_bib0011","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/JHC.S499763","article-title":"Transarterial chemoembolization plus radiofrequency ablation and iodine-125 seed implantation for hepatocellular carcinoma in high-risk locations: a propensity score-matched analysis","volume":"12","author":"Zhang","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"issue":"0","key":"10.1016\/j.brachy.2025.11.001_bib0012","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2147\/JHC.S480082","article-title":"TACE combined with portal vein tumor thrombus (125)I seed implantation in the treatment of HCC with hepatic arterioportal shunts","volume":"11","author":"Xia","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"issue":"0","key":"10.1016\/j.brachy.2025.11.001_bib0013","article-title":"Transarterial chemoembolization with (125)I seed insertion for multifocal hepatocellular carcinoma","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.brachy.2025.11.001_bib0014","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5114\/jcb.2020.96863","article-title":"Iodine-125 seed implantation for residual hepatocellular carcinoma or cholangiocellular carcinoma in challenging locations after transcatheter arterial chemoembolization: initial experience and findings","volume":"12","author":"Li","year":"2020","journal-title":"J Contemp Brachytherapy"},{"issue":"0","key":"10.1016\/j.brachy.2025.11.001_bib0015","article-title":"Combined ultrasound and CT-guided iodine-125 seeds implantation for treatment of residual hepatocellular carcinoma located at complex sites after transcatheter arterial chemoembolization","volume":"11","author":"Ren","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.brachy.2025.11.001_bib0016","first-page":"642","article-title":"Comparison of TACE combined with and without iodine-125 seeds implantation therapy for advanced stage hepatocellular carcinoma: a systematic review and meta-analysis","volume":"24","author":"Liu","year":"2019","journal-title":"J BUON"},{"issue":"2","key":"10.1016\/j.brachy.2025.11.001_bib0017","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10620-017-4899-x","article-title":"Efficacy of (125)I versus Non-(125)I combined with transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma with obstructive jaundice","volume":"63","author":"Li","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.brachy.2025.11.001_bib0018","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40644-023-00604-4","article-title":"Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study","volume":"23","author":"Guo","year":"2023","journal-title":"Cancer Imaging"},{"issue":"6","key":"10.1016\/j.brachy.2025.11.001_bib0019","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.brachy.2023.06.229","article-title":"Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"22","author":"Lin","year":"2023","journal-title":"Brachytherapy"},{"issue":"0","key":"10.1016\/j.brachy.2025.11.001_bib0020","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2147\/JHC.S525984","article-title":"Survival outcomes and prognostic factors of systemic therapy for advanced hepatocellular carcinoma: a multidisciplinary clinic experience from Saudi Arabia","volume":"12","author":"Asiri","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.brachy.2025.11.001_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000547264","article-title":"The neutrophil-to-lymphocyte ratio during Atezolizumab plus Bevacizumab therapy for unresectable hepatocellular carcinoma predicts long-term therapeutic efficacy: a multicenter analysis","volume":"7","author":"Sato","year":"2025","journal-title":"Oncology"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:40:51Z","timestamp":1772109651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472125003587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1538472125003587"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2025.11.001","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultrasound and CT-guided 125I implantation combined with TACE therapy in the treatment of recurrent HCC after RFA","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2025.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Brachytherapy Society.","name":"copyright","label":"Copyright"}]}}